The Fundrise iPO in 2026: $16.05 a Share for a Stock the Filing Calls 'Arbitrarily Determined', at 36x Its Own Book Value

Correction and update, September 19, 2026: this page said trailing-twelve-month Class B sales peaked at $54.8 million in July 2022. The peak disclosed in the circulars is $55.3 million, measured at January 26, 2023 — a row that was already printed in our own table on this page, which the sentence above it contradicted. The fall is 88.4%, not "about 88% from July 2022". We also paired the share count from the 10-Q cover page (32,607,343, as of July 31, 2026) with the June 30, 2026 balance sheet; both now come from June 30 (32,600,679 shares), a 6,664-share difference that does not move the multiple. Added: the Series A liquidation preference of $25,951,000, which ranks ahead of every common share and is nearly twice the entire common equity line, and which no earlier version of this page mentioned.

What this actually is

Fundrise calls it the iPO, for internet public offering. The lowercase "i" is doing real work, because it is not an IPO in any sense a normal investor would recognise. There is no exchange, no underwriter, no book-building, no float and no price discovery.

What it is: a Regulation A Tier 2 offering by Rise Companies Corp, the Delaware parent that owns Fundrise, LLC and Fundrise Advisors, LLC. It sells Class B Common Stock, and the offering circular restricts it: "We intend to limit the offer and sale of our Class B Common Stock in this offering solely to investors who have purchased one or more investments sponsored by us."

So the buyer pool is Fundrise's own customer base, the price is set by Fundrise's own board, and there is nowhere else for the shares to trade. Every input to the price comes from one side of the table. That is not an accusation, it is a structural description, and Rise says as much itself in language we will get to.

The price ladder, and the thing it has never done

Twenty price points over nine and a half years. Every single one is an increase. There has never been a markdown, not through 2020, not through the 2022 rate shock, and not through the commercial real estate drawdown that took double-digit percentages off the net asset values of Fundrise's own peers and, as it happens, off some of Fundrise's own funds.

The other thing the ladder shows is the pause. The price sat at $15.90 from May 2023 until August 2026, three years and three months, and then moved 0.94%. Read charitably, that is a board declining to mark itself up through a bad market, which is more discipline than the 2017-2022 run suggests. Read the other way, a mark that only ever goes up and then stops is not a price, it is a policy.

The demand number, which is the real story

Prices set by a board tell you what the board thinks. What buyers do tells you what buyers think, and Regulation A makes them disclose it, because a Tier 2 issuer has to test its sales against a rolling twelve-month cap.

The August 20, 2026 circular is unusually clear about this. Rise is offering up to 4,275,000 shares at $16.05, "for a total of up to $68.6 million, which represents the value of the shares available to be offered as of August 4, 2026 out of the rolling 12-month maximum offering amount of $75.0 million in our Class B Common Stock taking into account $6.4 million in shares of Class B Common Stock sold over the prior 12-month period."

And then: "Since this offering commenced on September 23, 2025, we have sold 352,854 shares at $15.90 per share for approximately $5.6 million in offering proceeds."

Roughly $5.6 million raised between September 23, 2025 and the circular's measurement date of August 4, 2026 — ten and a half months — while $68.6 million of room still sits unused. The $5.6 million is not a slice of the $68.6 million: the two are what has been sold and what remains available, and the sold figure is about 8% of the size of the room left.

Here is the same figure through time, taken from the rolling-cap disclosure in successive offering circulars:

The peak in that series is $55.3 million, measured at January 26, 2023 — not the July 2022 row, which is the one we anchored to when this page was first published on August 25, 2026 and which the table above already contradicted. From $55.3 million to $6.4 million is a fall of 88.4%. Every row is the rolling-cap disclosure on the cover of a Rise offering circular, and the cap itself changed: it was $50 million when Regulation A's Tier 2 limit was $50 million (the October 2020 row, measured at October 29, 2020) and $75 million from 2021 on. Cumulative gross raised across all of Rise's Regulation A offerings has crept from $211.3 million in September 2025 to $216.9 million in August 2026.

This is the same diagnostic we applied to Grant Cardone's 26 Form D filings, where $2.46 billion offered against $818 million sold gave a 33% fill rate. An offering's fill rate is the one demand signal a sponsor cannot set by committee, and here it is telling you that the customers who know Fundrise best have largely stopped buying its equity, while the price the board sets for that equity has only gone up.

What the company is worth, and what the filing says about that question

Rise Companies has been an Exchange Act reporting company since 2025, which means quarterly 10-Qs instead of the thinner Regulation A reports. The Form 10-Q for the quarter ended June 30, 2026 is the current picture.

Income statement, from the same filing and the FY2025 Form 10-K:

Two things in that table are easy to miss. The six-month revenue line is up nicely, $33.0 million against $28.0 million, and that is the number a summary would quote. But the second quarter on its own was down year over year, $15,487,000 against $16,008,000, a 3.3% decline. The growth is in the first quarter, not the most recent one. And the losses widened while revenue grew, in both the quarter and the half.

Now the arithmetic nobody publishes, and it has to be done on one date. The balance sheet is struck at June 30, 2026, and at that date the 10-Q reports 2,458,394 Class A, 20,142,285 Class B and 10,000,000 Class F shares outstanding: 32,600,679 common shares. Against $14,536,000 of stockholders' equity before non-controlling interests, that is $0.4459 of book value per common share. (The cover page of the same 10-Q gives a slightly later count, 32,607,343 shares as of July 31, 2026; pairing that with a June 30 balance sheet is what this page did until September 19, 2026. The difference is 6,664 shares and it does not move the multiple.)

At $16.05 the offering price is therefore about 36 times book, and the implied market value of the common is about $523 million. Include the 11,865,046 convertible preferred shares as converted and it is roughly $714 million; include the RSUs, PSUs and options as well and it is roughly $912 million.

The line that sits above you, and how big it is

Converting the preferred is the generous reading, because it treats those shares as common. The 10-Q describes the other reading, and it is the one that applies if the company is ever sold or wound up:

"Upon any liquidation, winding up or dissolution of the Company ... before any distribution or payment will be made to the holders of any Common Stock, the holders of convertible preferred stock will be entitled to receive ... an amount per share of Series A equal to $2.1872 ... plus all declared and unpaid dividends."

"Any excess assets, after payment in full of the liquidation preferences to the convertible preferred stockholders, are then allocated to the holders of the Common Stock, pro-rata."

The filing also says a sale of the company, a merger, or a transfer of more than 50% of the voting power all count as a liquidation event. So this is not a remote scenario; it is what happens on the exit a buyer of the iPO is implicitly hoping for.

The size of that claim is on the face of the balance sheet. 11,865,046 preferred shares × $2.1872 = $25,951,229, and the balance sheet states the aggregate liquidation preference as $25,951 thousand — it reconciles to the dollar. Set that against the company's own equity:

The preference is $25.95 million against $14.62 million of total common equity. It is not a slice of the common's book value; it ranks ahead of all of it, and it is nearly twice as large. On the liquidation waterfall rather than the GAAP book line, the residual to common is $13,683,000, or $0.42 per common share, which puts $16.05 at 38 times rather than 36.

Both numbers are ours and both are defensible: $0.4459 is book equity per common share as GAAP reports it, because the preferred sits in mezzanine and is already excluded from that $14,536,000. $0.42 is what is left for common after the preference is paid in a liquidation event. We are showing both because the gap between them is the point, and because our original figure was the one that flattered the issuer — the fuller reading of the same balance sheet makes the multiple worse, not better.

Those are our calculations, and we are labelling them as such, because Rise has never published a valuation and, more to the point, expressly says the price is not one:

"The price per share shown was arbitrarily determined by our board of directors and may be changed from time to time by our board of directors in its sole discretion."

"We established the offering price of our shares of Class B Common Stock on an arbitrary basis. The selling price of our shares bears no relationship to our book or asset values or to any other established criteria for valuing shares. Because the offering price is not based upon any independent valuation, the offering price may be substantially more than the actual value of your investment. Further, the offering price may be significantly more than the price at which the shares would trade if they were to be listed on an exchange or actively traded by broker-dealers."

I want to be fair about what that language is. It is boilerplate in the sense that many Regulation A issuers carry something like it, and it is genuinely more candid than most companies manage. Fundrise is not hiding this; it is on the cover and in the risk factors, and the word "arbitrarily" has been there since January 2017.

But candour about a disclaimer is not the same as a valuation. A software business losing $12 million a year on $57 million of revenue might well be worth several hundred million dollars. It might not. The point is that nothing in the offering tells you which, and the only number presented to buyers, the $16.05, is by the issuer's own description not evidence.

The part that deserves to be better known

Illiquidity in a private stock is expected. The specific terms here are not.

There is no repurchase programme. From the FY2025 10-K: "The Company does not currently have a publicly announced share repurchase program."

There is no market and no commitment to make one. From the risk factors: "Our amended and restated certificate of incorporation does not require us to list our shares for trading on a national securities exchange by a specified date. There is no public market for our shares and we currently have no plans to list our shares on a stock exchange or other trading market ... it will be difficult for you to sell your shares promptly or at all. If you are able to sell your shares, you would likely have to sell them at a substantial discount to the public offering price."

There is a soft aspiration: Rise "may consider alternatives for providing liquidity to our stockholders within three to five years from the completion of this offering," with "no assurance that a suitable transaction will be available." The circular also states plainly that Rise does "not have a stated term."

You cannot sell to a willing buyer without permission. Holders "may not transfer, assign, pledge or otherwise dispose of or encumber shares of Class B Common Stock ... without the prior written consent of our board of directors or our chief executive officer," who "may withhold consent to any prohibited transfer in its absolute discretion."

And the company can take the shares back at what you paid. This is the clause worth reading twice:

"pursuant to subscription agreements that we enter into with each holder of Class B Common Stock, we have the right to repurchase, at the original purchase price, all of the shares of Class B Common Stock held by a holder if such holder fails to conform their personal conduct to accepted standards of good citizenship or if such holder conducts itself in a way that reflects poorly on our company, as determined by our board of directors or chief executive officer in their sole discretion. If we repurchase your shares of Class B Common Stock under the above circumstances, you will not realize any profit on your shares, regardless of the current fair market value of those shares."

Put the two halves of this article together and the asymmetry is stark. The share price only ever goes up, and it is set by the board. The one circumstance in which the company can force a sale, it does so at the original purchase price, which after a decade of that upward-only ladder means handing back every dollar of the paper gain. And the standard triggering it is "accepted standards of good citizenship," judged by the board in its sole discretion.

We have found no evidence that Rise has ever exercised this clause, and we are not suggesting it has. It is a term in a contract that fifty thousand-odd people have signed, and it is not discussed anywhere outside the risk factors.

So who is this for

There is a coherent case for buying it, and it is worth stating properly rather than knocking down a weak version.

Fundrise is a real business with real revenue, over $57 million in 2025 and growing across the half. It has built distribution that most asset managers would envy: hundreds of thousands of funded accounts acquired without brokers, and a platform that can launch a fund and fill it from its own customer base. If you think that distribution eventually gets monetised through a sale or a listing, then buying equity in the manager rather than units in the funds is the higher-beta way to own it, and $16.05 may look cheap in hindsight.

Against that: the losses are widening, the most recent quarter's revenue went backwards, total assets have fallen 28% in six months, cash is at $8.4 million, and the demand curve for this very stock is down 88% from its peak. You are paying a price the issuer describes as arbitrary, for an asset with no market, no repurchase programme, no dividend and no committed exit, that you cannot transfer without permission and that can be reclaimed at cost.

The honest summary is that this is a venture-style bet on Fundrise the company, priced by Fundrise the company, sold only to Fundrise the company's customers, with no exit you can count on. Fundrise does take buyback requests through a login-only form, but only at its discretion and only at the price you originally paid (what the request page and the filing say). If you want that exposure and can lose it entirely, the case exists. If you were treating it as a way to "invest alongside" your Fundrise account, the terms above are the ones to read first.

Sources

• Rise Companies Corp, offering circular on Form 253G2, filed August 20, 2026 — accession 0001104659-26-099152. Price, minimum, availability, the trailing-twelve-month and since-inception sales figures, prior settled shares, the 506(c) placement, the "arbitrarily determined" language, the transfer and personal-conduct repurchase terms, the listing and liquidity language, and the dividend policy.
• Rise Companies Corp, Form 10-Q for the quarter ended June 30, 2026, filed August 7, 2026 — accession 0001628280-26-054711. Balance sheet, income statement, share counts by class, and accumulated deficit.
• Rise Companies Corp, Form 10-K for FY2025, filed March 23, 2026 — accession 0001628280-26-020484. Full-year revenue and loss, holders of record, and the statement that there is no announced share repurchase programme.
• Prior Rise Companies offering circulars on Form 253G2 and price-change notices on Form 1-U across File Nos. 024-10659, 024-11149, 024-12141 and 024-12664, for the price ladder and the rolling-cap sales history.

Implied valuations and the book-value multiple in this article are our own arithmetic on the disclosed figures, clearly labelled as such. Rise Companies has never published a valuation and states that its offering price is not based on one. Nothing here is investment advice. We hold no position in Rise Companies and earn no commission from Fundrise.